RPL22L1 and neoplasm: IHC analysis was performed on multi-tumor TMAs (S4 Fig), which revealed that RPL22L1 is highly expressed in a variety of solid tumors including renal cell carcinoma, breast cancer, lung cancer as well as colon sarcoma and colorectal carcinoma (Fig 3A–3C and S4 Fig).